HGEN's Lenzilumab excluded anyone with an O2 level below 94, so it's not a competitor to Leronlimab. Leronlimab that treats the most severe and critical patients, and will likely be used for at risk moderates too once doctors get more familiar with it.
When will word about sales in Philippines get out do you think? Do you think there will be a pr as to a sale of 200,000 vials, or will we see something along the lines that Chiral is filling sales request to various hospitals with no set number? If the later, I don't see much of a pop is sp as it is too ambiguous. I would like to see something more substantial about Brazil, rather than just a distribution agreement with no sales numbers.
News 
Market Data 
Discover 
